PT-141 (Bremelanotide): A Receptor Pharmacology and Literature Review

Stylised cyclic peptide ring over a dark background with five schematic receptor outlines in a membrane band and a small mass-spectrum trace below

The PT-141 peptide has an unusually well-documented receptor pharmacology and an unusually poorly understood mechanism — both at the same time, and both in the published record. This review is deliberately narrow: it covers what the literature reports about the molecule's structure and its interaction with melanocortin receptors, and nothing else. Clinical outcomes, indications and anything a reader might take as an expected effect are outside its scope and are not discussed here.

Identity and structure

PT-141 is the development name of bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It has been described in the literature as an analogue of melanotan II, the earlier cyclic α-MSH analogue from which the series derives; the name link appears explicitly in the primary literature, where the compound is introduced as “bremelanotide (PT-141), a melanocortin receptor agonist” (Diamond et al., 2006), and in the first-approval review of the molecule as a “synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone” (Dhillon and Keam, 2019).

Three structural facts do most of the pharmacological work:

  • It is cyclic. The peptide is closed into a ring, which constrains the backbone conformation. For an α-MSH analogue this matters because the receptor-recognition motif sits in a defined spatial arrangement rather than in a flexible linear chain.
  • It contains a D-amino acid. The prescribing information for the licensed product gives the structure as Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH), with a free acid at the carboxyl terminus. The His-D-Phe-Arg-Trp core is the recognisable melanocortin pharmacophore, with the phenylalanine in the D configuration.
  • It is a heptapeptide, not a fragment. Seven residues is short enough to synthesise and characterise cleanly, and long enough to carry the full recognition motif — unlike the minimal melanocortin fragments discussed below.

Cyclisation and D-amino-acid substitution are, in general peptide chemistry, structural strategies associated with resistance to peptidase cleavage. For the purposes of this review the point is narrower: the molecule's identity is fully specified, so characterisation of a lot is a solved analytical problem even where the biology is not.

The melanocortin receptor family

Melanocortin peptides are derived from pro-opiomelanocortin and act at a family of G-protein-coupled melanocortin receptors, conventionally numbered MC1R through MC5R. The relevant observation for PT-141 is that it does not respect those divisions. Reviews of its neurobiology state that bremelanotide nonselectively activates several of the receptor subtypes, of which subtype 4 — MC4R — is considered the most relevant (Pfaus et al., 2022).

Non-selectivity is a substantive pharmacological property, not a footnote. A compound that activates several subtypes in a family cannot have its behaviour attributed to one receptor without an experiment that isolates that receptor, and most of the published work on this molecule was not designed as a subtype-dissection study. “MC4R is the most relevant” is a judgement drawn from the weight of the literature, not a measured selectivity ratio.

For contrast within the same receptor family, the tripeptide KPV — α-MSH residues 11–13, the C-terminal end of the same parent hormone (Luger and Brzoska, 2007) — shows how differently a melanocortin-derived sequence can behave. The KPV literature reports that its effects are at least partly independent of MC1R (Kannengiesser et al., 2008), with cell work pointing to the PepT1 transporter and NF-κB and MAP-kinase signalling rather than to classical receptor agonism (Dalmasso et al., 2008). Same parent hormone, same nominal receptor family, very different mechanistic file — which is a useful warning against reasoning about melanocortin peptides as a class. KPV appears in this catalogue as a component of a multi-compound blend; we review its file alongside the others in CS-GLW and CS-KLW blends compared.

What the animal and cell literature reports

The most specific mechanistic statements in the record are from animal work, and they are framed as suggestions rather than conclusions. Animal studies suggest the compound acts on presynaptic MC4R on neurons in the medial preoptic area of the hypothalamus, with increased release of dopamine (Pfaus et al., 2022). That is a circuit-level and neurotransmitter-level observation in a model organism: a receptor population, a brain region, a measured neurochemical change.

Two reading disciplines apply. First, “suggest” is the authors' own verb, and presynaptic receptor localisation in a defined nucleus is a technically demanding claim. Second, a dopamine-release observation in a rodent hypothalamic preparation is a measurement in that preparation. Extending it to any other species or any functional outcome is an inference the papers do not make, and this review does not make it either.

Where the evidence stops — including on the mechanism itself

The sharpest statement in the whole file comes from the regulatory document rather than the research literature. The licensed product's label states that the mechanism by which it produces its clinical effect is unknown. A molecule can therefore have a resolved structure, a named receptor family, a nominated primary subtype and a candidate neural circuit, and still have an explicitly unknown mechanism of action in the only setting where its effects have been formally characterised. That gap is the most instructive thing about the compound.

The remaining limits, stated plainly:

  • Selectivity is unquantified in the sources reviewed here. Non-selective activation across subtypes is reported; a ranking with numbers is not.
  • Circuit mechanism is animal-derived and described by its authors as suggestive.
  • Regulatory status attaches to a licensed product, not to a reagent. Bremelanotide was approved in the USA in 2019 as a specific licensed medicine (Dhillon and Keam, 2019); randomized phase 3 trial results were published in the same period (Kingsberg et al., 2019) and a later re-analysis questioned the size of the reported benefit. That approval applies to the licensed product only. It says nothing about any research-use material, and research-grade peptide in a vial is not an approved product in any sense.

Characterisation and handling

A cyclic heptapeptide with a D-residue is an analytically tractable molecule. Reverse-phase HPLC resolves the main peak from synthesis-related impurities — for a cyclic peptide the relevant impurities include linear precursor and oligomeric side-products, which separate from the cyclised product; mass spectrometry confirms the molecular mass, which also distinguishes the cyclic product from an un-cyclised chain of the same composition. Each lot's certificate of analysis states the measured purity and identity for that specific lot.

FieldPT-141 (vial)PT-141 spray
IdentityBremelanotide; synthetic cyclic heptapeptide α-MSH analogueSame compound in solution
FormatLyophilised powder, glass vial, crimp seal, flip-top cap10 mL spray bottle, pump and overcap
Content10 mg10 mg at 1 mg/mL
House codeCS-PT141-10CS-PT141-SP-10
Storage−20 °C, desiccated, protect from light2 to 8 °C, protect from light
Lot documentationRP-HPLC identity and measured purity, mass confirmationRP-HPLC identity and measured purity, mass confirmation

The storage difference between the two formats is the chemistry, not a policy: a lyophilised solid is held frozen and dry, while a prepared aqueous solution is held refrigerated because peptides in solution are subject to hydrolysis and oxidation over time. Light protection applies to both — tryptophan and histidine residues are photosensitive, and this sequence contains both.

Frequently asked questions

What receptors does the PT-141 peptide act on?

Melanocortin receptors. The literature reports that bremelanotide non-selectively activates several subtypes in the family, with MC4R considered the most relevant. A quantified selectivity profile is not given in the sources reviewed here.

Is PT-141 the same thing as bremelanotide?

Yes — PT-141 is the development name and bremelanotide is the non-proprietary name for the same cyclic heptapeptide. Regulatory approval of a licensed bremelanotide medicine applies to that product alone, not to research-use material.

If the receptor is known, why is the mechanism called unknown?

Because receptor binding is not a mechanism of action. The licensed product's label states the mechanism behind its clinical effect is unknown, even though the receptor family, a nominated primary subtype and a candidate hypothalamic circuit have all been described in animal work.

How is a lot of a cyclic peptide characterised?

By RP-HPLC for chromatographic identity and measured purity, with mass spectrometry confirming the molecular mass — which for a cyclic peptide also separates the closed product from a linear chain of identical composition. The certificate is specific to the lot.

See it in the catalogue: PT-141.

For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.

California Standard Peptides

Your cart

0 items · free shipping over $200.00

Your cart is empty.

Buy 2 of a vial and save 10%, 3 and save 15%. Research sets are 15% off, and shipping is free over $200.00.

First order

20% off your first order.

Join the list for first word on new lots, restocks and member pricing. Your code arrives by email and applies by itself at checkout.

One code per email, for your first order. By signing up you agree to get emails from us. Unsubscribe anytime.

For laboratory research use only. 21+.